Tumor Immunity and Type I IFN

The antiproliferative and anti-angiogenic activities of type I interferons have paved the way for the use of these cytokines, in particular IFN-α, in clinical oncology. In some clinical settings, however, IFN-α has been superseded by newer anticancer drugs because of its severe side effects, which include autoimmunity, inflammation and tissue toxicity. IFN-λ1, a member of the type III interferon family, shows promise as an alternative antiviral and antiproliferative agents, as the rela­tively limited expression of its receptor may preclude the hematological toxicity associated with type I interferon. Meanwhile, the recently described effects of type I interferons on DCs and other cells of the immune response support the rationale for using type I interferon molecules as adjuvants for the generation of more effective cancer vaccines.

 

(Click image below to download a PDF)

 

Tumor Immunity and Type I Interferon

Find your product of interest by searching for category, species, molecule and/or application.

Visit our blog to read about recent developments in the fields of interferon, cytokine and biomarker research!

Sign up for our mailing list to be kept up-to-date on the latest promotions, company and product news.

Go to top